?? Elevate your research with Science 42: #DORA—now at 50% off for a limited time. This advanced #AI-driven tool from Insilico Medicine makes drafting professional #scientificdocuments faster and more efficient. Visit the DORA website to get started today: https://bit.ly/3XoW8eR #blogs #writing #academics #conferenceabstracts
Insilico Medicine
生物技术研究
Boston，Massachusetts 58,002 位关注者
#insilicomeds, #drugdiscovery, #ai, #GANs, #GANs-RL, #DL #aging, #longevity
关于我们
Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
- 网站
-
https://www.Insilico.com
Insilico Medicine的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Boston，Massachusetts
- 类型
- 私人持股
- 创立
- 2014
- 领域
- artificial intelligence、deep learning、reinforcement learning、drug discovery、aging research、longevity、biomarker development、Generative adversarial networks、GANs和GANs-RL
地点
Insilico Medicine员工
动态
-
Last week, we announced our latest #PCC targeting WRN. So far, we've accumulated 20 PCCs under our belt with our #AI-powered end-to-end platform in less than four years. I’d like to take you back to our first PCC and the journey that started it all. This video highlights the critical success of our validation phase, particularly the bleomycin-induced mouse model test, where our molecule demonstrated both safety and efficacy in the in vivo model. This success was a significant boost to our confidence and marked a pivotal moment in our drug discovery process. #DrugDiscovery #AI #Innovation #Healthcare #InVitro #InVivo #ClinicalTrials #InsilicoMedicine #MedicalResearch #Pharma #Biotech #Validation
-
Welcome to Boston, Insilico Medicine panel with Antonio Regalado, Vadim Gladyshev, and Alex Zhavoronkov
-
-
-
-
-
+15
-
-
? Join this incredible panel at the Fierce Biotech Summit next week in Boston! Explore the recovery of the #biotech industry and look ahead to a brighter future. Fierce Biotech Fierce Life Sciences Events Michelle Chen #FierceBiotechSummit
Join us at the #FierceBiotechSummit for this featured session on September 30-Oct 1, 2024 ?REGISTER NOW! Save up to $300 with the Advanced Rate: https://ow.ly/lXMK50SWXUY ??What to Expect: In the session "Decoding AI in Drug Development", you'll explore how artificial intelligence is revolutionizing the drug development process. Experts will discuss the latest AI applications in identifying drug targets, optimizing clinical trials, and predicting outcomes. Attendees can expect to gain valuable insights into how AI is driving efficiency, innovation, and precision in biotech, transforming the way new therapies are developed and brought to market. A big thank you to our moderator and speakers: - Karim Budhwani from CerFlux - Mark Brenckle from Alkermes - Gavin Corcoran, MD FACP from Formation Bio - Michelle Chen from Insilico Medicine - Jeffrey Reid from Regeneron Stay Updated by following Fierce Life Sciences Events #FierceBiotech #Biotech #FiercePharma #Pharma #Innovation
-
-
???? Using Amazon SageMaker, Insilico has improved its model training capabilities, enhancing its solutions for accelerating #drugdiscovery. Insilico now has two systems that benefit from the advanced models that were trained on Amazon SageMaker: PandaOmics, a solution that empowers researchers to identify potential therapeutic targets, and Chemistry42, a comprehensive #small-molecule drug discovery platform. Using AI and ML on Amazon Web Services (AWS), Insilico will continue its groundbreaking work in discovering new targets and developing innovative molecules in pursuit of life-changing drugs to combat diseases. “Our mission is to extend healthy, productive longevity for everyone,” says Petrina Kamya, Ph.D., global head of AI platforms for Insilico. “That is what we set our minds to every day when we come into work.” Read the full case study here: https://lnkd.in/ebRq_i7R
-
???? Prague.bio begins today! Catch Jan Szollos, MBA onsite for all things #PharmaAI.
Insilico Medicine is now back at the Prague.bio conference. Same as last year, the event is taking place in a beautiful location in the heart of Prague. It's also great to catch up with the growing community of #pharma, #biotech, and #ai #drugdiscovery companies and investors active in the CEE region. Kudos to the organizers, sponsors, and supporters! Jiri Fusek SanaClis i&i Biotech Fund Nicolas Beuzen Kamil Kuca Ján Kme?ko
-
-
https://lnkd.in/euQ-wgKx ?? Don't miss this important discussion on #GenerativeAI in Drug Discovery and #longevity, featuring Alex Wang and Alex Zhavoronkov!
Learn AI Together - I share my learning journey into AI and Data Science here, 90% buzzword-free. Follow me and let's grow together!
Join us for a live interview on Generative AI in Drug Discovery & Longevity. I invited Dr.Alex Zhavoronkov, Founder and CEO at Insilico Medicine, who's been a pioneer in this space for over two decades. With a Ph.D. in Biotechnology, Alex has been at the forefront of combining bioinformatics with deep learning, specializing in longevity. He's published numerous papers in top-tier scientific journals like Nature and Science Translational Medicine. After announcing Insilico Medicine at the NVIDIA GTC conference in 2015, the company has made remarkable breakthroughs: By 2019, Insilico validated its Chemistry42 platform in Nature Biotechnology, demonstrating that they could use deep learning models to produce a de novo small molecule that was tested and validated in animal studies. Today, the company has: - A lead AI-designed drug in Phase II trials for idiopathic pulmonary fibrosis - Nine compounds received IND approval - World leading end-to-end Generative AI platform across Biology, Chemistry Medicine and Science - 31 drugs in the pipeline, targeting cancer, fibrosis, immunology, IBD, and COVID-19 … In our conversation, we'll dive into Dr. Zhavoronkov's vision, latest research, and innovations in longevity, and explore the crucial role Generative AI plays in shaping the future of medicine. Don't miss out – join us live for this insightful conversation! ? Make sure to subscribe (click '????????????') to receive the recording. #artificialintelligence #generativeai #technology #healthcare #innovation
Join us | GenAI in Drug Discovery & Longevity with Dr. Alex Zhavoronkov
www.dhirubhai.net
-
?? Tutorial: How to generate a #reviewpaper using Science42: #DORA (Draft Outline Research Assistant) Get a deeper look at how the review papers are created below: #publications #casestudies
-
Just in case you missed the news. Dose-dependent improvements in FVC after 12 weeks is a remarkable achievement for any biotech. And since I am familiar with how the drug was discovered and the technology risks we had to take - I still can not believe it all worked to get us to this point. Huge thanks to the team!
-
-
Our team is onsite at #EUROQSAR 2024! Insilico Medicine Co-Founder and President, Alex Aliper, PhD, will be at the 24th EUROQSAR symposium this week in Barcelona, Spain joined by Arkadii Lin, Team Lead in #Chemoinformatics. The presentation will take place on September 26: #Chemistry42: Combining #GenerativeChemistry and Next-Generation Binding Free Energy Engine for Lead Identification and #Optimization (SL14) Be sure to visit Poster #P126 onsite and don't miss this Thursday's presentation! https://bit.ly/3zvxzVC
-